Research-grade specs Components: CJC-1295 No DAC (GHRH analog) + Ipamorelin (GHSR ligand) 5 MG vial: CJC-1295 5 mg + Ipamorelin 5 mg (10 mg total) 10 MG vial: CJC-1295 10 mg + Ipamorelin 10 mg (20 mg total) CJC-1295 length: 30 amino acids Half-life: ~30 minutes for the No DAC variant, reported in published literature Format: Lyophilized powder, single-vial blend Studied applications GHRH + GHRP receptor-pathway synergy research Pulsatile GH-release studies Comparative research vs the CJC-1295 With DAC variant Receptor-selectivity comparison against each compound alone Quality & trust 99% HPLC purity, third-party tested Mass spectrometry identity confirmation LAL endotoxin testing on every batch Batch-specific Certificate of Analysis included cGMP manufactured in Dallas, Texas (USA) USA same-day shipping (orders before 2pm CT M-F) Free domestic shipping on orders over $200 Storage & handling Store lyophilized vials refrigerated at 28C, protected from light and heat Reconstitute with bacteriostatic water

Treatment with either NR or the PARP inhibitor Olaparib resulted in improvements at the mitochondrial and proteostasis level
Package Size
At this concentration: 1mg dose = 0.03mL (3 units on U-100 insulin syringe) 2mg dose = 0.06mL (6 units) 3mg dose = 0.09mL (9 units) 5mg dose = 0.15mL (15 units) You can adjust concentration by adding more or less water
IV acetylcysteine may be especially preferable because it achieves higher serum drug levels and avoids vomiting (of course, IV acetylcysteine is generally the treatment of choice regardless of pregnancy status)
Appropriate patient selection, informed consent, and ongoing monitoring are essential